File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Prognostic Value of Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease

TitlePrognostic Value of Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease
Authors
KeywordsADPKD
FGF23
Issue Date2021
Citation
Kidney International Reports, 2021, v. 6, n. 4, p. 953-961 How to Cite?
AbstractIntroduction: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive cyst growth and a loss of functioning renal mass, but a decline in glomerular filtration rate (GFR) and onset of end-stage renal disease (ESRD) occur late in the disease course. There is therefore a great need for early prognostic biomarkers in this disorder. Methods: We measured baseline serum fibroblast growth factor 23 (FGF23) levels in 192 patients with ADPKD from the Consortium for Radiologic Imaging Studies of PKD (CRISP) cohort that were followed for a median of 13 years and tested the association between FGF23 levels and change over time in height-adjusted total kidney volume (htTKV), GFR, and time to the composite endpoints of ESRD, death, and doubling of serum creatinine. Results: Patients in the highest quartile for baseline FGF23 level had a higher rate of increase in htTKV (0.95% per year, P = 0.0016), and faster rate of decline in GFR (difference of −1.03 ml/min/1.73 m2 per year, P = 0.005) compared with the lowest quartile, after adjusting for other covariates, including htTKV and genotype. The highest quartile of FGF23 was also associated with a substantial increase in risk for the composite endpoint of ESRD, death, or doubling of serum creatinine (hazard ratio [HR] of 2.45 in the fully adjusted model, P = 0.03). Conclusion: FGF23 is a prognostic biomarker for disease progression and clinically important outcomes in ADPKD, and has additive value to established imaging and genetic biomarkers.
Persistent Identifierhttp://hdl.handle.net/10722/316185
ISSN
2023 Impact Factor: 5.7
2023 SCImago Journal Rankings: 1.377
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorEl Ters, Mireille-
dc.contributor.authorLu, Pengcheng-
dc.contributor.authorMahnken, Jonathan D.-
dc.contributor.authorStubbs, Jason R.-
dc.contributor.authorZhang, Shiqin-
dc.contributor.authorWallace, Darren P.-
dc.contributor.authorGrantham, Jared J.-
dc.contributor.authorChapman, Arlene B.-
dc.contributor.authorTorres, Vicente E.-
dc.contributor.authorHarris, Peter C.-
dc.contributor.authorBae, Kyongtae Ty-
dc.contributor.authorLandsittel, Douglas P.-
dc.contributor.authorRahbari-Oskoui, Frederic F.-
dc.contributor.authorMrug, Michal-
dc.contributor.authorBennett, William M.-
dc.contributor.authorYu, Alan S.L.-
dc.date.accessioned2022-08-24T15:49:32Z-
dc.date.available2022-08-24T15:49:32Z-
dc.date.issued2021-
dc.identifier.citationKidney International Reports, 2021, v. 6, n. 4, p. 953-961-
dc.identifier.issn2468-0249-
dc.identifier.urihttp://hdl.handle.net/10722/316185-
dc.description.abstractIntroduction: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive cyst growth and a loss of functioning renal mass, but a decline in glomerular filtration rate (GFR) and onset of end-stage renal disease (ESRD) occur late in the disease course. There is therefore a great need for early prognostic biomarkers in this disorder. Methods: We measured baseline serum fibroblast growth factor 23 (FGF23) levels in 192 patients with ADPKD from the Consortium for Radiologic Imaging Studies of PKD (CRISP) cohort that were followed for a median of 13 years and tested the association between FGF23 levels and change over time in height-adjusted total kidney volume (htTKV), GFR, and time to the composite endpoints of ESRD, death, and doubling of serum creatinine. Results: Patients in the highest quartile for baseline FGF23 level had a higher rate of increase in htTKV (0.95% per year, P = 0.0016), and faster rate of decline in GFR (difference of −1.03 ml/min/1.73 m2 per year, P = 0.005) compared with the lowest quartile, after adjusting for other covariates, including htTKV and genotype. The highest quartile of FGF23 was also associated with a substantial increase in risk for the composite endpoint of ESRD, death, or doubling of serum creatinine (hazard ratio [HR] of 2.45 in the fully adjusted model, P = 0.03). Conclusion: FGF23 is a prognostic biomarker for disease progression and clinically important outcomes in ADPKD, and has additive value to established imaging and genetic biomarkers.-
dc.languageeng-
dc.relation.ispartofKidney International Reports-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectADPKD-
dc.subjectFGF23-
dc.titlePrognostic Value of Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease-
dc.typeArticle-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1016/j.ekir.2021.01.004-
dc.identifier.scopuseid_2-s2.0-85101322355-
dc.identifier.volume6-
dc.identifier.issue4-
dc.identifier.spage953-
dc.identifier.epage961-
dc.identifier.isiWOS:000639562600011-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats